Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / TNF

TNF

Basics

Aliases:
This biomarker is also known as:
  • tumor necrosis factor-alpha,
  • Tumor necrosis factor ligand superfamily member 2,
  • DIF,
  • TNFSF2,
  • TNF superfamily, member 2,
  • tumor necrosis factor (TNF superfamily, member 2),
  • cachectin,
  • TNF, macrophage-derived,
  • TNFA,
  • TNF, monocyte-derived,
  • APC1 protein,
  • tumor necrosis factor alpha,
  • TNF-alpha,
  • Cachectin,
  • TNF-a,
  • tumor necrosis factor,

View in BioMuta

Description…

TNF (tumor necrosis factor) is a cytokine involved in many biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. TNF belongs to the TNF superfamily. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. TNF binds to its receptors TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR, through which it functions. It is involved in cellular responses to stimuli such as cytokines and stress and plays a key role in regulating the immune response to infection. This cytokine is a pyrogen, causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia. TNF has been implicated in a variety of diseases, including autoimmune diseases, insulin resistance, and cancer. Knockout studies in mice also suggest this cytokine has a neuroprotective function. TNF is cleaved into two chains, tumor necrosis factor, membrane form and tumor necrosis factor, soluble form.

Attributes

QA State: Under Review
Type: Protein
Short Name:
HGNC Name: TNF

Datasets

There are no datasets associated with this biomarker.

Organs

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Publications

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Resources

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.